HYLA Completes First Production Run on New 4500 Puff Vape System

CAVE CREEK, AZ, Sept. 27, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire – Endexx Corporation (OTC:EDXC), a provider of innovative, plant-based, and sustainable health and skincare products, today announces that its recently acquired (controlling-interest) HYLA division, secured two major purchase orders for its new innovative vape-delivery product that holds 4500 puffs per built in cartridge unit.

Combined, the orders represent a 150,000-unit order and a 52,000-unit order for over 200,000 units within the first month of the acquisition of Hyla. The newly innovated "No-Nic" (zero- nicotine) vape product produced by HYLA offers 4500 puffs per disposable unit. This expanded puff capacity far exceeds the capacity of its competitor's products worldwide. Formulated with Guarana and Levodopa, this product is forecasted to replace the recently banned nicotine products sold internationally where vape products are available.

Todd Davis, CEO of Endexx, stated "HYLA's new product line fills a major gap created by the banning of flavored nicotine vape products. We believe plant-derived products are the alternative and the solution that meets market demands today. The two purchase orders came from prominent distributors in the West Coast region of the US and a large western region in Asia. These orders expand both our international and domestic distribution networks helping to expedite our growth initiatives."

About Hyla

Hyla develops and distributes zero-nicotine plant-powered, vape-delivered products made with vegan formulations and functional plant extract ingredients. Hyla harnesses the power of Guarana and Levodopa to create plant-derived high-performance botanical products. For more information: 

About Endexx Corporation

Endexx Corporation develops and distributes all natural, plant-derived topical skincare products.  Its products vary from balms, creams, lotions, butters, masks, scrubs, and oils, all with the shared purpose of healthy skin and grooming wellness.  The science behind these products involves a decade of clinical research in the field and lab work to provide functional formulation with ingredients for optimal absorption and support of skin health.

Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995

We caution that any forward-looking statements (as such term is defined in the U.S. Private Securities Litigation Reform Act of 1995) contained in this press release or made by us, our management, or our spokespeople involve risks and uncertainties and are subject to change based on various factors, many of which are beyond our control. Accordingly, our future performance and financial results may differ materially from those expressed or implied in any such forward-looking statements. Forward-looking statements include, without limitation, statements regarding our future operating results, the implementation and impact of our strategic plans, and our ability to meet environmental, social, and governance goals. Words such as "estimate," "commit," "target," "goal," "project," "plan," "believe," "seek," "strive," "expect," "anticipate," "intend," "potential" and any similar expressions may identify forward-looking statements. Risks associated with the following factors, among others, could affect our financial performance and cause actual results to differ materially from those expressed or implied in any forward-looking statements:

Except as may be required by law, we assume no obligation and do not intend to make publicly available any update or other revisions to any of the forward-looking statements contained in this press release to reflect circumstances existing after the date of this press release or to reflect the occurrence of future events, even if experience or future events make it clear that any expected results expressed or implied by those forward-looking statements will not be realized. More information on potential factors that could affect our results is included "Risk Factors" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 31, 2022.

For further information, please contact:

Endexx Corporation
Endexx@endexx.com
480-595-6900

Investors:
Scott Arnold
CORE IR
scotta@coreir.com

Media:
Jules Abraham
CORE IR
julesa@coreir.com
917-885-7378